To evaluate the efficacy and safety of induction chemotherapy combined with tislelizumab as neoadjuvant therapy in patients with locally advanced squamous cell carcinoma of the external auditory canal; to explore the improvement in the preservation rate of important neurovascular structures (including the facial nerve, internal carotid artery canal, sigmoid sinus, and posterior cranial nerves, etc.).
Age > 18 years old and ≤ 80 years old
Pathologically confirmed as squamous cell carcinoma
Suitable for enhanced MRI/CT imaging assessment
Previously untreated squamous cell carcinoma of the external auditory canal staged as cT3-4NxM0 according to the Pittsburgh clinical staging system
Ear tumors whose pathological type is not squamous cell carcinoma
Patients with early-stage (T1-T2) disease or distant metastasis (M1)
Cases not jointly discussed with an otologist
Non-first-time radiotherapy for the head and neck region